Nonpeptide Somatostatin Type 5 Receptor Agonists and Uses Thereof
Summary
USPTO granted patent US12600709B2 to Crinetics Pharmaceuticals covering nonpeptide somatostatin type 5 receptor agonists, methods of making the compounds, pharmaceutical compositions, and methods of using the compounds in treating conditions that benefit from somatostatin modulation. The patent includes 4 claims.
What changed
USPTO issued patent US12600709B2 to Crinetics Pharmaceuticals covering nonpeptide somatostatin type 5 receptor agonists, pharmaceutical compositions containing these compounds, and methods of using them to treat conditions that would benefit from somatostatin activity modulation. The patent names Jian Zhao, Yunfei Zhu, Shimiao Wang, Mi Chen, and Joseph Pontillo as inventors and contains 4 claims.
For pharmaceutical manufacturers and drug developers, this patent establishes intellectual property protection around somatostatin S5 receptor modulation technology. Parties developing similar somatostatin modulators or related therapeutic compounds should conduct freedom-to-operate analyses to assess potential infringement risks. The patent may also represent licensing opportunities for entities seeking access to somatostatin receptor agonist technology.
What to do next
- Monitor for licensing opportunities
- Review patent claims for freedom-to-operate analysis
Archived snapshot
Apr 14, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Nonpeptide somatostatin type 5 receptor agonists and uses thereof
Grant US12600709B2 Kind: B2 Apr 14, 2026
Assignee
CRINETICS PHARMACEUTICALS, INC.
Inventors
Jian Zhao, Yunfei Zhu, Shimiao Wang, Mi Chen, Joseph Pontillo
Abstract
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
CPC Classifications
C07D 401/04 C07D 401/14 A61P 3/10
Filing Date
2024-09-03
Application No.
18822733
Claims
4
Related changes
Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.